MMED has become one of the more charged setups in the med-tech space: short sellers have aggressively rebuilt positions over the past six weeks, yet the stock is up 10% on the week alone and has held near $12.30. The result is a rare and uncomfortable standoff — a heavily shorted name that refuses to fall.
The short interest data tells a striking story. Bears have more than doubled their position since late April. SI as a percentage of the free float was roughly 6.7–7% at end of April. It cleared 12% by mid-May, jumped again above 13% in the third week of the month, and then broke through 17% in the final days of May — landing at 17.6% as of June 2. That's a move of more than 30% in a single week and 123% over the month. The official FINRA fortnightly reading confirms it: 4.28 million shares short, with days-to-cover at 7.18. Short sellers have not drifted in — they have planted a flag.
Yet the borrow market tells a less hostile story than those numbers might suggest. Cost to borrow has actually eased, dropping about 26% on the week to just over 1% annualised — among the cheapest borrow rates in the sector. Availability is at 167% of short interest, meaning there are roughly 1.7 shares available to lend for every share already borrowed. The borrow pool is far from stressed. That looseness explains how shorts could build so quickly without blowing up financing costs — the lending market has accommodated the demand without friction. The ORTEX short score of 69, down modestly from a recent peak of 72.4, reflects the elevated but not extreme overall short setup.
Options positioning has shifted sharply in bulls' favour — and that's the real tension with the short-interest picture. The put/call ratio has collapsed from above 8.9 (where it sat for most of April and early May, near the 52-week high of 9.66) to just 1.45 now. The z-score on that ratio is -1.04, meaning the PCR is running more than one standard deviation below its 20-day average of 5.1. In plain terms: the options market has rotated hard from extreme defensiveness toward call-buying. Shorts are rebuilding, but the options crowd is not hedging alongside them — it is pressing the other way.
The Street is broadly constructive on MMED, though with some nuance. Morgan Stanley, Wells Fargo, Barclays, Citigroup, Mizuho, Evercore, and William Blair all initiated coverage at Buy-equivalent ratings in late March, clustering around targets of $19–26. Benchmark added a fresh Buy at $20 in mid-May. B of A Securities is the one note of caution: Travis Steed maintained his Buy but cut the target from $27 to $20 in the most recent action (May 18). The consensus mean target is $21.27 — a 73% premium to the current price of $12.30. Bears cite margin compression from pricing pressure, reimbursement risk, and product concentration. Bulls point to the company's position in the growing diabetes management market and improving fundamentals, with the ORTEX stock score rising from 40 to 59 over the past two months. Valuation is modest — the PE sits around 17x and EV/EBITDA at 5.6x — which may explain why the rising short interest has not translated into price weakness.
The ownership picture adds another layer. Medtronic holds 90% of shares outstanding, leaving only a thin public float. That structural tightness matters: when shorts are at 17.6% of a small float and options traders are buying calls, the feedback loop on any positive catalyst can amplify fast. One CEO sale — 4,809 shares at $16.31 in March — is the only insider transaction on record, and at $78K it is too small to read as a signal either way.
What to watch: the gap between the FINRA settlement date (May 15) and the current estimate-based reading of 17.6% suggests the next official disclosure will either confirm or complicate the bear thesis — and given that the borrow market remains loose, whether shorts continue to absorb that supply or begin to unwind in the face of the stock's continued resilience will determine which side blinks first.
See the live data behind this article on ORTEX.
Open MMED on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
